Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05128032 · ClinicalTrials.gov registry record · NA

Pressure-enabled Delivery in Radioembolization (TriNav Study)

A NA study of Hepatocellular Carcinoma and Liver Cancer, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
20
Enrollment target
2
Study locations

NCT05128032 is a NA study of Hepatocellular Carcinoma and Liver Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05128032, a NA study of Hepatocellular Carcinoma and Liver Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: * Pressure Enabled Drug Delivery (PEDD)/TriNav Infusion System * Standard 2.4F microcatheter, not otherwise specified

Conditions Studied

Hepatocellular Carcinoma Liver Cancer Metastatic Colorectal Cancer

Interventions

  • DEVICE Standard microcatheter
  • DEVICE PEDD device

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-03-01
Est. Completion 2026-09-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05128032

The ClinicalTrials.gov registry entry for NCT05128032 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Standard microcatheter is the first listed.

NCT05128032 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05128032 about?

NCT05128032 is a clinical study titled "Pressure-enabled Delivery in Radioembolization (TriNav Study)". The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: * Pressure Enabled Drug Delivery (PEDD...

What is the current status of trial NCT05128032?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-03-01. Estimated completion is 2026-09-01.

What conditions does trial NCT05128032 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Metastatic Colorectal Cancer.

What interventions are being tested in trial NCT05128032?

The interventions under investigation include: Standard microcatheter (DEVICE), PEDD device (DEVICE).

Who is sponsoring clinical trial NCT05128032?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05128032 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Liver Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.